I'm not sure I can trust somebody who joined this board less than a month and pretend to be here for long. Sorry, my shares and many other longs are not for sale. I feel you are affiliated to potential buyer who want to bargain here and get ELTP at a cheap price. We can't be fooled :) and we have seen many like you that came and gone. Here are some facts that might be helpful
Elite Pharmaceuticals (ELTP): Acquisition & Valuation Analysis
Executive Summary
Elite Pharmaceuticals (ELTP) has transitioned from a small generic manufacturer into a rapidly scaling specialty-generic company with accelerating revenue, expanding manufacturing capacity, and a high-value ANDA pipeline. Fiscal 2025 revenue was $84M, but the company has already generated $80M in Q1–Q2 of Fiscal 2026, placing it on track for $160M for the full year.
This report evaluates ELTP’s 3-year revenue outlook, intrinsic valuation, buyout valuation, and competitive landscape. It also incorporates the impact of three major upcoming ANDA opportunities:
Generic OxyContin (oxycodone ER)
Generic Concerta (methylphenidate ER)
A blockbuster anticoagulant with $27B in branded annual sales
These products materially increase ELTP’s long-term revenue potential and strategic acquisition value.
1. Revenue Forecast (2026–2028)
Baseline Assumptions
Fiscal 2025 revenue: $84M
Fiscal 2026 forecast: $160M (supported by Q1–Q2 results)
Growth moderates as the company scales but remains strong due to new ANDA launches and expanded capacity.
Base Case Forecast
Fiscal Year Revenue YoY Growth Key Drivers
2025A $84M — Existing portfolio
2026E $160M +90% ADHD franchise, new launches
2027E $208M +30% OxyContin/Concerta contributions
2028E $250M +20% Anticoagulant launch, scale efficiencies
Bull Case Forecast
Assumes strong market share in ADHD, pain, and anticoagulant categories.
Year Revenue
2026 $160M
2027 $240M
2028 $300M
Bear Case Forecast
Assumes faster price erosion and slower ANDA approvals.
Year Revenue
2026 $160M
2027 $184M
2028 $202M
2. DCF Valuation
Key Inputs
Net margin: 18%
FCF conversion: 80%
Discount rate (WACC): 12%
Terminal growth: 2.5%
Shares outstanding: 1.07B
Projected Free Cash Flow
Year Revenue Net Income Free Cash Flow
2026 $160M $28.8M $23M
2027 $208M $37.4M $30M
2028 $250M $45M $36M
DCF Result
Present value of FCF: $72M
Terminal value (discounted): $420M
Intrinsic value: ~$492M
Intrinsic value per share: ~$0.46
This valuation does not include the impact of the major ANDAs discussed below.
3. Strategic ANDA Impact Analysis
Three upcoming products significantly increase ELTP’s long-term value:
A. Generic OxyContin (Oxycodone ER)
Large, stable ER opioid market
High barriers to entry
Expected revenue contribution: $20M–$40M annually
B. Generic Concerta (Methylphenidate ER)
ADHD market remains robust
Complex ER formulation limits competition
Expected revenue contribution: $25M–$40M annually
C. Anticoagulant Generic (Branded sales: $27B annually)
This is the most transformative opportunity.
Even minimal market share yields massive revenue:
Market Share Annual Revenue Net Income (25–35% margin)
1% $270M $70M–$95M
2% $540M $140M–$190M
3% $810M $200M–$280M
This single product could double or triple ELTP’s valuation.
4. Revised Buyout Valuation
Revenue Multiple Method
Using 2028 revenue potential including ANDAs:
Low case (2× revenue): $950M
Mid case (3× revenue): $1.4B–$2.7B
High case (4× revenue): $4.4B
EBITDA Multiple Method
Assuming 25% EBITDA margin on $250M–$1.1B revenue:
EBITDA range: $62M–$275M
Acquisition multiples (10×–14×):
$620M – $3.8B
Premium Method
Current market cap ˜ $500M
Typical acquisition premium: 20–50%
$600M – $750M (baseline, without ANDA impact)
⭐ Revised Strategic Buyout Range
$1.5B – $3.0B
Per-share equivalent: $1.40 – $2.80
If the anticoagulant performs at the high end, valuation could exceed $4B.
5. Competitive Threat Assessment
Major Competitors
Teva
Amneal
Lannett
Mallinckrodt
Rhodes
Aurobindo
Lupin
Threat Level by Category
Product Category Threat Level Notes
ADHD (Vyvanse, Adderall, Concerta) High Many ANDA filers, price erosion
Pain Management (OxyContin ER, Methadone) Medium Fewer competitors, stable demand
CNS / Parkinson’s Low–Medium Smaller markets, higher margins
Contract Manufacturing Low Sticky relationships, high switching costs
Conclusion
Elite Pharmaceuticals is entering a multi-year expansion phase driven by:
Strong revenue acceleration
High-value ANDA pipeline
Expanded manufacturing capacity
A clean balance sheet
Entry into multi-billion-dollar therapeutic categories
The company’s intrinsic value is rising rapidly, and its strategic acquisition value could realistically reach $1.5B–$3.0B, with upside beyond $4B depending on anticoagulant market penetration.
Market Data 
Markets 
